Under the terms of the agreement, Belharra will receive $80M up front & is eligible for ~$2B in development & commercial milestones incl. tiered royalties in exchange for the worldwide rights to develop & commercialize small molecule therapies in oncology, immuno-oncology, autoimmune & neurodegenerative diseases
In addition, Belharra received an option to co-develop certain oncology & autoimmune therapies through P-I & co-fund the remaining development in exchange for US cost/profit split & ex-US milestone payments & royalties
Belharra will be responsible for the discovery & early preclinical development whereas Genentech will look after the target selection & late preclinical, clinical & commercial activities
Ref: Businesswire | Image: Belharra
Related News:- Sosei Heptares Entered into a Drug Discovery Collaboration with Eli Lilly to Develop and Commercialize Small Molecules for Diabetes and Metabolic Diseases
